Is adalimumab protective in ischemia-reperfusion injury in lung?

Kurt A., TUMKAYA L., Kalkan Y., TÜRÜT H., CURE M. C., CURE E., ...More

IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, vol.18, no.11, pp.1093-1099, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 18 Issue: 11
  • Publication Date: 2015
  • Journal Name: IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1093-1099
  • Keywords: Adalimumab, Endothelin-1, Ischemia reperfusion, Lung injury, Tumor necrosis factor-alpha, RHEUMATOID-ARTHRITIS, ENDOTHELIN-1, MALONDIALDEHYDE, INFLIXIMAB, APOPTOSIS, SAFETY
  • Recep Tayyip Erdoğan University Affiliated: Yes

Abstract

Objective(s): Increasing cytokines and reactive oxygen species (ROS) during ischemia reperfusion (I-R) leads to the lung damage. Adalimumab (Ada) is a potent tumor necrosis factor-alpha (TNF-alpha) inhibitor agent. We aimed to evaluate whether Ada would prevent the lung tissue from damage development over the I-R process.